A review of a trial of lowering LDL cholesterol to new targets casts doubt – by Dr Glen Davis


Millions of individuals worldwide are currently being treated with cholesterol lowering statin drugs based on the recommendations of the most recent guidelines on cholesterol management.

The 2018 American Heart Association (AHA)/American College of Cardiology (ACC) cholesterol guidelines, like their European counterpart, are intended to reduce the risk of future cardiovascular disease by establishing targets for lowering low density lipoprotein cholesterol (LDL-C)

Although this approach is supported by substantial evidence, it has never been validated.

To test the validity of this paradigm, this analysis will critically review the clinical outcomes of randomised controlled trials (RCTs) of cholesterol reduction


*As noted in Dr Glen Davies presentations at the GP CME Conference in June 2020